ArticleCPT: pharmacometrics & systems pharmacology2023
Consistent methods for fat-free mass, creatinine clearance, and glomerular filtration rate to describe renal function from neonates to adults.
Article in CPT: pharmacometrics & systems pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 23 citations in OpenAlex.
- Application of Pharmacometric Modelling Towards Precise Dosing in Neonates, Infants and Toddlers: A Scoping Review.Clinical pharmacokinetics · 2026Review
- Model-Informed Dose Optimization of Anakinra in Preterm Neonates Implications for Safe and Effective Dosing.Clinical pharmacology and therapeutics · 2026Article
- Impact of Febrile State on Vancomycin Clearance in Pediatric Patients: Insights From Population Pharmacokinetic Modeling.Pharmaceutical research · 2026Article
- Advancing Pediatric Dose Scaling: Strategies, Modeling Approaches, and Clinical Applications.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Preliminary Evidence for Sex Differences in CYP2C19 Metabolic Capacity During Psychotropic Drug Treatment.Genes · 2026Article
- Model-informed precision dosing of vancomycin in children 3 months to 18 years of age using Australia-wide data.Antimicrobial agents and chemotherapy · 2026Article
- Population Pharmacokinetics and Dosing Simulations of Pentobarbital in the Pediatric Population.Journal of clinical pharmacology · 2026Observational
- Causal relationship between serum creatinine levels and bone mineral density: A Mendelian randomization study.Medicine · 2026Article
- Therapeutic drug monitoring of amikacin in Chinese premature infant: a population pharmacokinetic analysis and dosage optimization.BMC infectious diseases · 2025Article
- A Physiologically Based Modeling Approach to Evaluate Intravenous Levetiracetam Dosing in Term and Preterm Neonates.Journal of clinical pharmacology · 2025Article
- Personalized tobramycin dosing in children with cystic fibrosis: an AUCAntimicrobial agents and chemotherapy · 2025Observational
- Exploring the Influence of Obesity and CYP2 C19 Genotype on Lansoprazole Pharmacokinetics in Pediatric Patients: A Population Modeling Approach.Clinical pharmacokinetics · 2025Article
- Physiologically Based and Population Pharmacokinetic Modeling of Midazolam in Children With Obesity Using Real-World Data.Clinical and translational science · 2025Article
- Spotlight commentary: Changes in pharmacokinetics following significant weight loss.British journal of clinical pharmacology · 2025Article
- A Review of Vancomycin, Gentamicin, and Amikacin Population Pharmacokinetic Models in Neonates and Infants.Clinical pharmacokinetics · 2025Review
- Personalized Dosing of Medicines for Children: A Primer on Pediatric Pharmacometrics for Clinicians.Paediatric drugs · 2024Review
- Characterizing Enoxaparin's Population Pharmacokinetics to Guide Dose Individualization in the Pediatric Population.Clinical pharmacokinetics · 2024Article
- Time-Varying Clearance in Milrinone Pharmacokinetics from Premature Neonates to Adolescents.Clinical pharmacokinetics · 2024Article
- When will the Glomerular Filtration Rate in Former Preterm Neonates Catch up with Their Term Peers?Pharmaceutical research · 2024Article
- Tofacitinib pharmacokinetics in children and adolescents with juvenile idiopathic arthritis.CPT: pharmacometrics & systems pharmacology · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Quantifying the effect of kidney disease on glomerular filtration rate (GFR) is important when describing variability in the clearance of drugs eliminated by the kidney. We aimed to develop a continuous model for renal function (RF) from prematurity to adulthood based on consistent models for fat-free mass (FFM), creatinine production rate (CPR), and GFR. A model for fractional FFM in premature neonates to adults was developed using pooled data from 4462 subjects and 2847 FFM observations. It was found that girls have an FFM higher than that predicted from adult women based on height, total body mass, and sex, and boys have an FFM lower than adult men until around the onset of puberty, when it approaches adult male values. Data from 108 subjects with measurements of serum creatinine (Scr) and GFR were used to construct a model for CPR. Creatinine clearance was predicted using a model for CPR (based on FFM, postmenstrual age, and sex) and Scr that avoids discontinuous predictions between neonates, children, and adults. Individual CPR may then be used with individual Scr to predict the estimated GFR (eGFR; eGFR = CPR/Scr). A previously published model for human GFR based on 1153 GFR observations in 923 subjects without known kidney disease was updated using the model for fractional FFM to predict individual size and age-consistent values for the expected normal GFR (nGFR). Individual renal function was then calculated using RF = eGFR/nGFR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.